Efferocytosis of SARS-CoV-2-infected dying cells impairs macrophage anti-inflammatory functions and clearance of apoptotic cells

Ana CG Salina†, Douglas dos-Santos†, Tamara S Rodrigues†, Marlon Fortes-Rocha†, Edismauro G Freitas-Filho†, Daniel L Alzamora-Terrel†, Icaro MS Castro‡, Thais FC Fraga da Silva§, Mikhail HF de Lima¶, Daniele C Nascimento¶¶, Camila M Silva¶¶¶, Juliana E Toller-Kawahisa¶¶¶¶, Amanda Becerra¶, Samuel Oliveira¶, Diego B Caetité¶¶¶, Leticia Almeida¶¶¶¶, Adriene Y Ishimoto¶, Thais M Lima¶¶, Ronaldo B Martins¶, Flavio Veras¶¶, Natália B do Amaral¶¶, Marcela C Giannini¶¶, Letícia P Bonjorno¶¶, Maria IF Lopes¶¶, Maira N Benatti¶¶, Sabrina S Batah¶¶, Rodrigo C Santana¶¶, Fernando C Vilar¶¶, Maria A Martins¶¶, Rodrigo L Assad¶¶, Sergio CL de Almeida¶¶, Fabiola R de Oliveira¶¶, Eurico Arruda Neto¶, Thiago M Cunha¶¶, José C Alves-Filho¶¶¶, Vania LD Bonato¶¶, Fernando Q Cunha¶¶¶, Alexandre T Fabro¶¶¶, Helder I Nakaya¶¶¶¶, Dario S Zamboni¶¶¶¶, Paulo Louzada-Junior¶¶¶¶, Rene DR Oliveira¶¶¶¶, Larissa D Cunha¶¶¶¶†

†Departamento de Biologia Celular e Molecular e Bioagentes Patogênicos, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, Brazil; ‡Hospital Israelita Albert Einstein, Sao Paulo, Brazil; ¶Departamento de Bioquímica e Imunologia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, Ribeirão Preto, Brazil; §Departamento de Farmacologia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, Brazil; ¶¶Center of Research in Inflammatory Diseases (CRID), Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, Brazil; ¶¶¶Divisão de Imunologia Clínica, Emergência, Doenças Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, Brazil; ¶¶¶¶Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, Brazil; ¶¶¶¶Departamento de Cirurgia e Anatomia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, Brazil

Abstract COVID-19 is a disease of dysfunctional immune responses, but the mechanisms triggering immunopathogenesis are not established. The functional plasticity of macrophages allows this cell type to promote pathogen elimination and inflammation or suppress inflammation and promote tissue remodeling and injury repair. During an infection, the clearance of dead and dying cells, a process named efferocytosis, can modulate the interplay between these contrasting functions. Here, we show that engulfment of SARS-CoV-2-infected apoptotic cells exacerbates inflammatory cytokine production, inhibits the expression of efferocytic receptors, and impairs continual efferocytosis by macrophages. We also provide evidence supporting that lung monocytes and macrophages from severe COVID-19 patients have compromised efferocytic capacity. Our findings reveal that dysfunctional efferocytosis of SARS-CoV-2-infected cell corpses suppresses macrophage...
anti-inflammation and efficient tissue repair programs and provides mechanistic insights for the excessive production of pro-inflammatory cytokines and accumulation of tissue damage associated with COVID-19 immunopathogenesis.

Editor's evaluation
The lung and other organ damage sustained during Covid-19 disease results predominantly from the immune response to SARS-CoV-2, which includes inflammation. In this paper the authors investigated potential mechanisms, and determined that part of the reason is the interaction of SARS-CoV-2 with macrophages, the cells of the innate immune response which have multiple roles, including efferocytosis, which is the engulfment of apoptotic cells, removing these cells and their debris. They found that SARS-CoV-2 virus is still viable in the apoptotic cells, and leads to an increase in macrophage production of inflammatory cytokines, as well as decreases their efferocytosis capability. In combination, these effects may lead to a more dysregulated immune response to the virus.

Introduction
Patients with severe and critical COVID-19 progress from pneumonia to development of acute respiratory distress syndrome and respiratory failure, septic shock, and multiorgan dysfunction (Siddiqi and Mehra, 2020). These severe clinical manifestations of the disease are caused by dysregulated host immune response, including compromised function of the myeloid compartment (Blanco-Melo et al., 2020; Lucas et al., 2020; Rodrigues et al., 2021; Schulte-Schrepping et al., 2020; Silvin et al., 2020; Valle et al., 2020; Veras et al., 2020). Therefore, hyperinflammation and extensive unresolved tissue damage associated with dysfunctional innate responses should contribute to the pathogenesis of inflammatory lung disease and worsening of COVID-19, although underlying mechanisms are still loosely defined.

Macrophages and monocytes are functionally plastic cells that can promote homeostasis and resolution of inflammation by sensing microbial and host-derived signals and programming their gene expression toward an anti-inflammatory, pro-resolution, and wound-healing phenotype (Martins et al., 2019; Trzebanski and Jung, 2020). This host-protective programming reduces inflammatory cytokine production by other immune and non-immune cells and promotes the repair of damaged tissue to sustain physiological function and re-establish homeostasis (Murray and Wynn, 2011). During the repair process, the efficient clearance of dying cells prevents further tissue dysfunction caused by uncontrolled cytotoxicity and the release of damage-associated molecular patterns (DAMP). Defects in sensing, ingesting, and degradation of dead and dying cells through efferocytosis cause chronic inflammation and autoimmune diseases (Boada-Romero et al., 2020). In addition to preventing the deleterious effects of secondary necrosis, efferocytosis also couples corpse internalization to other environmental cues (such as local cytokines and metabolites) to temporally and spatially regulate macrophage anti-inflammatory and tissue repair functions (A-Gonzalez et al., 2017; Bosurgi et al., 2017; Perry et al., 2019). While the clearance of apoptotic cells (AC) is often associated with alternative macrophage programming, the identity of the dying cell, the type of cell death, and the context of death (either sterile or infectious) can modulate the nature of the macrophage response (Rothlin et al., 2021).

While infection with SARS-CoV-2 induces the recruitment of immune cells to the lungs, their role in host defense and the causes for the dysfunction during disease progression remain elusive. Here, we sought to determine how macrophages operate when responding to dying epithelial cells infected with SARS-CoV-2. We found that the presence of viable SARS-CoV-2 in cell corpses dysregulates macrophage anti-inflammatory responses to the efferocytosis of AC, promoting excessive production of inflammatory IL-6 and IL-1β while disrupting the efficient continual clearance of dead cells required for effective tissue repair. We also provide evidence that the expression of efferocytic genes is reduced in macrophages from severe COVID-19 patients. Therefore, SARS-CoV-2 infection and the clearance of infected dying cells disrupt macrophage host-protective functions associated with immunopathological manifestations of COVID-19.
Results

Macrophages engulf dying cells carrying viable SARS-CoV-2

SARS-CoV-2 infection causes cytopathic effects in human and primate epithelial cells (Chu et al., 2020; Zhu et al., 2020), possibly mediated by activation of multiple cell death pathways (Chan et al., 2020; Li et al., 2020a; Li et al., 2020b; Mulay et al., 2021; Ren et al., 2020; Zhu et al., 2020). Notably, inhibition of apoptosis ameliorates cytokine expression and tissue damage in the lungs of SARS-CoV-2-infected mice, indicating that apoptosis in the lungs is pathogenic (Chu et al., 2021). Agreeing with previous reports (Chu et al., 2020; Ren et al., 2020; Zhu et al., 2020), infection with SARS-CoV-2 for 48 hr induced caspase-3 and caspase-8 activation in immortalized simian kidney epithelial Vero CCL81 (Figure 1A) and human lung epithelial Calu-3 cell lines (Figure 1A and B). We also found features consistent with the predominance of AC death at 48 hr post-infection by flow cytometric analysis of the pattern of annexin V and a permeability dye co-staining in infected cells (Figure 1C). Consistently, we observed low levels of cytolysis in these infected cells, as assessed by lactate dehydrogenase release (Figure 1D). Immunofluorescent labeling of cleaved caspase-3 in lung tissues of deceased COVID-19 patients confirmed the induction of apoptosis in the epithelia infected with replicant SARS-CoV-2 (Figure 1E, and Figure 1—figure supplement 1A). Examination of lung tissues also revealed evidence of macrophages with internalized epithelial cells and SARS-CoV-2, suggesting the uptake of infected epithelial cells by macrophages (Figure 1F).

We performed the median tissue culture infection dose (TCID50) assay and found that viral particles obtained from isolated apoptotic Vero and Calu-3 cells induced cytopathic effect to an equivalent extent as those released in the culture supernatants (Figure 1—figure supplement 1B). Furthermore, we isolated annexin V-labeled AC from SARS-CoV-2-infected cell culture and confirmed that they carry viable viral particles (Figure 1G). Therefore, viable SARS-CoV-2 is retained within infected, apoptotic epithelial cells.

Exposure of phosphatidylserine (PtdSer) on the outer plasma membrane of cells undergoing regulated cell death, as observed by annexin V binding to infected dying cells (Figure 1C), is the most ubiquitous signal that triggers their phagocytosis (Fadok et al., 1992; Nagata, 2018). To determine whether phagocytes efficiently engulf SARS-CoV-2-infected AC (CoV2-AC), we collected the loosely attached AC from infected cultures and used flow cytometry to assess their uptake by primary human macrophages and macrophages differentiated from THP-1 monocytes. We observed that macrophages efficiently engulf CoV2-AC, similarly to the uptake of sterile, UV-irradiated AC (UV-AC) (Figure 1H and Figure 1—figure supplement 1C). Analysis by confocal microscopy and staining for Spike protein confirmed the presence of SARS-CoV-2 in engulfed cell corpses (Figure 1—figure supplement 1D). Finally, either stimulation with infected or sterile dying cells did not robustly affect macrophages viability up to 24 hr post-treatment (Figure 1—figure supplement 1E).

These results demonstrate that macrophages engulf cell corpses carrying viable particles of SARS-CoV-2, offering a framework to investigate their effects on macrophage function.

Efferocytosis of SARS-CoV-2-infected dying cells impairs macrophage anti-inflammatory function

We next addressed the effect of the engulfment of SARS-CoV-2-infected AC in macrophages. The uptake of sterile AC often promotes macrophage functional polarization toward an anti-inflammatory and tissue repair phenotype (Doran et al., 2020). We first observed that stimulation of primary monocyte-derived macrophages with CoV2-AC, but not infection with SARS-CoV-2, reduced the expression of genes associated with alternative programming to tissue remodeling and secretion of immune-modulatory mediators such as CCL18, CD206 (also known as MRC1), MMP9, PPARG, and CD163 (Figure 2A). Furthermore, stimulation with UV-AC obtained from infected Vero cells increased both gene (Figure 2A) and surface protein (Figure 2B, Figure 2—figure supplement 1A) expression of the anti-inflammatory marker CD206. However, upregulation of MRC1 at the gene or protein levels did not occur in response to stimulation with CoV2-AC (Figure 2A and B). We obtained similar results in THP-1-derived macrophages stimulated with CoV2-AC obtained from either Calu-3 or Vero cells infected with SARS-CoV-2 (Figure 2—figure supplement Figure 2—figure supplement 1B-D). Stimulation with the conditioned supernatants of infected dying cells (containing putative DAMP, cytokines produced by epithelial cells, extracellular vesicles, and released virions) or direct infection with SARS-CoV-2 did not induce MRC1 transcription (Figure 2A, Figure 2—figure supplement 1B) or
**Figure 1.** Macrophages engulf apoptotic cells (AC) carrying viable SARS-CoV-2. (A) Immunoblot of caspase-8 and caspase-3 cleavage in Calu-3 and Vero CCL81 cells in response to infection with SARS-CoV-2 for 48 hr (CoV2, detected with rabbit anti-Spike), UV irradiation (UV), or freezing and thawing (F/T). (B) Flow cytometric analysis of caspase-3 cleavage (Cl-caspase-3) in Calu-3 cells unstimulated (Cntrl) or infected with CoV2 for 48 hr. The pan-caspase inhibitor z-VAD-FMK (zVAD; 20 μM) or vehicle (DMSO) was added to cell cultures after viral adsorption. Representative histogram, geometric mean fluorescence, and % of cells.

*Figure 1 continued on next page*
mean fluorescence intensity (MFI), and frequency of Cl-caspase-3+ cells (gated on total cells/single cells) are shown. The black line on the histogram represents the control sample labeled with secondary antibody only. (C) Flow cytometric analysis of apoptosis in Vero CCL81 cells in response to UV light irradiation or 48 hr post-infection with CoV2, assessed by annexin V (FITC) and viability dye (Zombie NIR) co-staining. Representative histogram and represents the control sample labeled with secondary antibody only. (C) Flow cytometric analysis of apoptosis in Vero CCL81 cells in response to UV light irradiation or 48 hr post-infection with CoV2. (E, F) Representative histological findings in post-mortem lung tissue from COVID-19 patients obtained by ultrasound-guided minimally invasive autopsy. (E) Immunofluorescence images of tissue samples labeled with anti-Cl-caspase-3 (red), anti-dsRNA (green), and stained with Hoechst (nuclei, blue) for the detection of caspase-3 activation in infected epithelia (COVID-19; bottom panels) compared to samples from control patients (Cntrl, upper panels). Tissues were scanned by wide-field epifluorescence imaging. Scale bar: 20 μm, asterisks: erythrocytes. The MFI of Cl-caspase-3 of at least 300 cells is shown (n=3 individuals per group). Technical control for secondary antibodies background is shown in Figure 1—figure supplement 1. (F) Representative immunofluorescence image of a COVID-19 patient tissue sample labeled for the detection of efferocytosis in situ and superimposed with differential interference contrast. Samples were labeled with anti-CD68 (detecting macrophages, green), anti-cytokeratin18 (CK-18, detecting epithelial cells, white), anti-Spike (detecting SARS-CoV-2, red), and stained with Hoechst (nuclei, blue). Bottom panels show higher magnification of (a, b) CD68+ macrophage with CK-18 and Spike labeling in the cytosol and (c) CD68+ only macrophage. White arrows: CK-18+ cells; asterisks: erythrocytes. Tissues were scanned by wide-field epifluorescence imaging. Scale bar: 20 μm; scale bar for insets: 10 μm. (G) Quantification by TCID50 of SARS-CoV-2 viral loads in Vero CCL81 cells infected for 48 hr. Viral loads were estimated for pre-sorted (total cells) or annexin V+ (Ann+ cells) cells isolated by magnetic separation. (H) Uptake of apoptotic Vero CCL81 cells (labeled with CTFR) in response to UV irradiation (UV-AC) or infection with SARS-CoV-2 for 48 hr (Cov2-AC) by human monocyte-derived macrophages (labeled with CellTrace Violet (CTV)). Macrophages were co-incubated with AC for 2 hr, and internalization was assessed by flow cytometry. Representative plot and percentage of engulfment (gated on total cells/single cells/live cells/CTV+/CTFR+ cells) are shown. Boxes represent the mean of five (B, D), four (C, H), or three (G) biological replicates, and error bars are ± S.E.M. Each biological replicate is shown as a circle. Significance was calculated by ANOVA (B-D), Mann-Whitney test (E), or Student’s t-test (G, H). *p<0.05, **p<0.001, ***p<0.0001, comparing the indicated groups. Data shown are from one representative out of two (A, C, G) or three (B, D, H) experiments performed independently with similar results.

The online version of this article includes the following source data and figure supplement(s) for figure 1:

Source data 1. Source data for Figure 1.

Figure supplement 1. Support data for Figure 1.

Figure supplement 1—source data 1. Source data for Figure 1—figure supplement 1.

surface expression (Figure 2B, Figure 2—figure supplement Figure 2—figure supplement 1C and D) in macrophages. We also confirmed that modulation of CD206 expression occurred specifically in the macrophages that engulfed AC and was not due to paracrine signaling (Figure 2C and Figure 2—figure supplement 1E). To determine if viral viability was required to modulate CD206 expression by infected AC, isolated CoV2-AC were exposed to UV irradiation for virus inactivation (Figure 2—figure supplement 1F). Notably, macrophages treated with epithelial AC containing inactivated SARS-CoV-2 exhibited increased CD206 surface expression, similar to that of UV-AC (Figure 2D). This finding suggests that viable SARS-CoV-2 actively represses alternative programming carried in dying cells and is not primarily enforced by the type of cell death caused by the infection. Efferocytosis of sterile UV-AC in the presence of SARS-CoV-2 still induced higher expression of CD206 in macrophages (Figure 2E). Therefore, the suppression of CD206 surface expression required delivery of viral particles within cell corpses to macrophages.

Conversely, the uptake of CoV2-AC, but not UV-AC, significantly increased IL6 expression in monocyte- and THP-1-derived macrophages (Figure 3A and Figure 3—figure supplement 1A, respectively). The uptake of CoV2-AC also induced robust secretion of inflammatory IL-6 and IL-1β, in both primary (Figure 3B) and THP-1-derived macrophages (Figure 3—figure supplement 1B and C). We did not detect these cytokines in macrophages stimulated with the cell-free conditioned supernatants (Figure 3B and Figure 3—figure supplement 1A-C), and therefore this effect was not due to immune mediators or viral particles released from infected epithelial cells. Importantly, assessment of IL-6 secretion in macrophages stimulated with sorted out populations of infected dying cells revealed that cytokine production occurred specifically in response to AC, but not permeabilized dead cells (Figure 3C). In agreement, CoV2-AC obtained from epithelial cells infected in the presence of osmo-protectant glycine, which non-specifically prevents the leak of cytosolic content by lytic permeabilization (Frank et al., 2000; Evavold et al., 2018) still induced robust secretion of IL-6 by macrophages (Figure 3—figure supplement 1D).

Further, the induction of inflammatory cytokines by SARS-CoV-2-loaded corpses required the presence of viable viral particles, as UV treatment or paraformaldehyde (PFA) fixation of isolated
CoV2-AC abrogated IL-6 secretion (Figure 3D). Notably, we did not observe robust production of IL-6 in response to dying epithelial cells infected with Coxsackievirus (Figure 3—figure supplement 1E and Figure 3E). This result suggests that augmented pro-inflammatory cytokine production is not a universal response of macrophages to the uptake of cell corpses infected with positive single-strand viruses.
Figure 3. Engulfment of SARS-CoV-2-infected dying cells causes inflammatory cytokine production. Macrophages were left unstimulated (Cntrl), co-incubated with apoptotic Vero CCL81 cells (AC) isolated from UV-irradiated (UV-AC) or SARS-CoV-2-infected (CoV2-AC) cultures, stimulated with the supernatants of infected apoptotic cells (CoV2-AC Sup), or infected with CoV2, as indicated. (A) IL6 expression in primary human monocyte-derived macrophages 24 hr after stimulation showed as fold change relative to Cntrl. mRNA expression was determined by RT-qPCR and normalized to GAPDH. (B) Cytometric bead array quantification of IL-6 and IL-1β in the culture supernatants of the monocyte-derived macrophages 24 hr after stimulation. (C, D) ELISA quantification of IL-6 in the culture supernatants of THP-1-derived macrophages 24 hr after stimulation. (E) Macrophages were stimulated with early AC (annexin V+ Zombie−) or late AC (annexin V+ Zombie+) sorted out by flow cytometry. (F) Where indicated, isolated CoV2-AC were UV-irradiated (UV) for 20 min or fixed with 2% paraformaldehyde (Fix) for 10 min prior to co-incubation. (E–H) ELISA quantification of IL-6 in the culture supernatants of human primary monocyte-derived macrophages 24 hr after stimulation. (E) IL-6 secretion in response to CoV2-AC was compared to AC isolated from Vero CCL81 cells similarly infected with Coxackievirus (Coxackie-AC). (F) Phosphatidylserine on the surface of CoV2-AC was blocked by incubation with annexin V (Ann, 0.1 μg/mL) prior to addition to macrophage cultures to inhibit AC binding. (G) CoV2-AC and macrophages were co-incubated in the presence of cytochalasin D (Cyto D, 10 μM) to inhibit AC internalization. (H) Macrophages were treated with Remdesivir (Remd, 20 μM) following stimulation with CoV2-AC to inhibit viral RNA transcription. Boxes represent the mean of three biological replicates using cells from a single donor (A, B, F, G), two donors (E), or THP-1-derived cells (C, D), and error bars are ± S.E.M. Each biological replicate is shown as a circle. Significance was calculated by ANOVA: *p<0.05, **p<0.001, ***p<0.0001, comparing the indicated groups. Data shown are from one representative out of at least two experiments performed independently with similar results.

The online version of this article includes the following source data and figure supplement(s) for figure 3:

*Figure 3 continued on next page*
To confirm the requirement of recognition and binding of CoV2-AC to promote inflammatory skewing, we stimulated macrophages in the presence of annexin V to mask PtdSer exposed on the surface of the AC. In the absence of PtdSer ligation, macrophages did not secrete IL-6 in response to CoV2-AC (Figure 3F and Figure 3—figure supplement 1F). Stimulation of macrophages in the presence of actin depolymerization inducer Cytochalasin D, which allows corpse binding but not internalization, also attenuated IL-6 production (Figure 3G). Finally, we tested the effect of antiviral drugs targeting viral RNA transcription (RdRP-mediated RNA synthesis). We found that Remdesivir treatment of primary macrophages following stimulation with CoV2-AC partially reduced IL-6 secretion, suggesting that viral sgRNA expression is important to modulate the inflammatory response (Figure 3H).

Collectively, these findings support that sensing and engulfment of dying cells carrying viable SARS-CoV-2 switch macrophage anti-inflammatory, resolutive programming in response to efferocytosis toward an inflammatory phenotype. The exacerbated cytokine production observed in response to the efferocytosis of infected cell corpses by macrophages may contribute to the cytokine storm associated with COVID-19 hyperinflammatory syndrome.

**Efferocytosis of SARS-CoV-2-infected dying cells suppresses continual clearance of apoptotic cells**

Several receptors mediate efferocytosis through recognition of PtdSer on the surface of a dying cell, either by direct binding or through a bridging molecule (Boada-Romero et al., 2020; Penberthy and Ravichandran, 2016). We found that engulfment of CoV2-AC by primary macrophages reduced the transcription of such PtdSer receptors, including the scavenger receptors CD36 and SRA1, αVβ5 integrin (ITGB5), and T cell immunoglobulin mucin receptor 4 (TIM4) and MER proto-oncogene tyrosine kinase (MERTK) (Figure 4A). In THP-1-macrophages, we also observed reduced expression of SRA1, ITGB5, and TIM4 receptors in response to infection with SARS-CoV-2 (Figure 4—figure supplement 1A). Phagocytes can ingest multiple corpses in subsequent rounds of efferocytosis (Miyanishi et al., 2007; Morioka et al., 2018; Park et al., 2011; Yurdagul et al., 2020). Previous in vivo work showed that macrophages must continually remove ACs to promote efficient repair of injury and prevent the accumulation of secondarily necrotic cells (Wang et al., 2017; Yurdagul et al., 2020). To determine if repression of efferocytic receptors affects additional uptake of dying cells, we treated macrophages with CoV2-AC and subsequently fed them with apoptotic human Jurkat cells (UV-Jurkat). We found that the engulfment of SARS-CoV-2-infected corpses suppressed the efferocytosis of other AC (Figure 4B–E, Figure 4—figure supplement 1B). As infection with SARS-CoV-2 reduced the expression of some efferocytic receptors in THP-1 macrophages (Figure 4—figure supplement 1A), we also tested if it affected the uptake of AC. Comparatively, infection with SARS-CoV-2 reduced AC clearance to a lower extent than prior uptake of CoV2-AC (Figure 4—figure supplement 1C). Notably, treatment with Remdesivir did not improve the subsequent uptake by macrophages stimulated with CoV2-AC, arguing that viral RNA replication is not required for suppression of efferocytosis in response to CoV2-AC (Figure 4F). This result also suggests that different mechanisms lead to pro-inflammatory cytokine production and efferocytosis repression in response to the uptake of infected corpses.

Thus, efferocytosis of SARS-CoV-2-infected dying cells affects the expression of efferocytic receptors and impairs the continual removal of AC by macrophages.

**Lung monocytes and macrophages of severe COVID-19 patients express reduced levels of efferocytic receptors**

To gain insight into the contribution of dysfunctional efferocytosis in COVID-19 pathogenesis, we assessed the expression of efferocytic receptors by immunofluorescence in lung tissues obtained from autopsies of deceased COVID-19 patients. We found a reduction in the protein levels of CD36 in S1009+ infiltrating phagocytes in the lungs of COVID-19 patients compared to control tissues.
Figure 4. Engulfment of SARS-CoV-2-infected dying cells suppresses continual efferocytosis by macrophages. 
(A) Expression of efferocytic receptors in human primary monocyte-derived macrophages. Macrophages were left unstimulated (Cntrl), co-incubated for 24 hr with apoptotic Vero CCL81 cells (AC) isolated from UV-irradiated (UV-AC) or SARS-CoV-2-infected (CoV2-AC) cultures, or infected with CoV2 (CoV2), as indicated. Expression of CD36, SRA1, ITGB5, TIMD4 and MERTK was assessed by flow cytometry. 

Figure 4 continued on next page
IL-6 and IL-1β, suggesting a mechanism for the robust secretion of cytokines related to COVID-19 that the uptake of cell corpses infected with SARS-CoV-2 exacerbates the secretion of inflammatory cytokines. While such causal connection remains to be investigated, our histological findings are consistent with the notion that uptake of infected cells reduces the capacity of macrophages to clear other dead cells. Altogether, these data support that macrophages in the lungs of severe COVID-19 patients may also fail in their efferocytic capacity.

**Discussion**

Patients with severe COVID-19 develop life-threatening inflammatory process in the lungs with underlying causes still not established. Here, we demonstrate that the sensing and engulfment of SARS-CoV-2-infected dying cells by macrophages switch the effector response to efferocytosis from a potential wound healing, anti-inflammatory function to a pro-inflammatory one. Our data supports that the uptake of cell corpses infected with SARS-CoV-2 exacerbates the secretion of inflammatory cytokines and may contribute to the robust secretion of cytokines related to COVID-19. Another important consequence of this shift in macrophage function is the impairment of macrophage capacity to engulf AC continually and promote proper injury resolution. Instead, this process may consequently contribute to respiratory complications developed by patients with the severe form of the disease and increase susceptibility to secondary bacterial infections for the lack of effective disease tolerance mechanisms that restrain collateral tissue damage (Jamieson et al., 2013). While such causal connection remains to be investigated, our histological findings are consistent with the notion that uptake of infected cells reduces the capacity of macrophages to clear other dead cells. Altogether, these data support that macrophages in the lungs of severe COVID-19 patients may also fail in their efferocytic capacity.
Figure 5. Lung monocytes and macrophages of severe COVID-19 patients express reduced levels of efferocytic receptors. 

(A–B) Representative histological findings in post-mortem lung tissue from control patients (Ctrl) and COVID-19 patients, obtained by ultrasound-guided minimally invasive autopsy. Tissue samples were immunolabeled with anti-S100A9 (phagocytes, green), (A) anti-CD36 (red), or (B) anti-MERTK (red) and stained with DAPI (nuclei, blue). Representative images show cropped details of lung tissues scanned by wide-field epifluorescence imaging. Scale bar: 10 μm. The mean fluorescence intensity (MFI) of CD36 and MERTK of at least 300 S100A9+ cells are shown (n=6 control and four COVID-19 patient samples). Dots represent an S100A9+ cell (A and B), the crossing line represents the mean, and error bars are ± S.E.M. Significance was calculated by Mann-Whitney test (A and B), *p<0.05, **p<0.001, ***p<0.0001, comparing the indicated groups. 

(C) Gene set enrichment analysis for efferocytosis-related gene sets in early infiltrating phagocytes (S100A9+ CCL18-) and in anti-inflammatory monocytes-derived macrophages (CD14+ S11009- CCL18+) clusters from the bronchoalveolar lavage of mild (-M Figure) and severe (-S) COVID-19 patients versus healthy individuals. The corrplot depicts the normalized enrichment score (NES), and p value for the gene sets indicated on the y-axis. 

(D) Enriched efferocytosis-related gene ontology (GO) terms in genes repressed in virus-positive versus virus-negative alveolar macrophages.

The online version of this article includes the following source data for figure 5:

Source data 1. Source data for Figure 5.
assessment and reanalysis of scRNAseq datasets suggest that the efferocytic capacity of lung macrophages is impaired in the lungs of COVID-19 patients.

In the context of COVID-19 immunopathogenesis, excessive amounts of necrotic cells may lead to high levels of circulating DAMP, such as HMGB1 and lactate dehydrogenase (LDH), both of which correlate with disease severity (Chen et al., 2020; Han et al., 2020; Rodrigues et al., 2021). It is thus possible that the combination of exacerbated cytokine production and interruption of continual efferocytosis in response to engulfment of SARS-CoV-2-infected corpses could both increase the magnitude and duration of inflammation, contributing to the hyperinflammatory state and multiorgan damage in COVID-19. Finally, some studies reported higher levels of autoantibodies (such as against IFNγ, phospholipids, and annexin A2) in COVID-19 patients (Bastard et al., 2020; Zuniga et al., 2021; Zuo et al., 2020), suggesting that autoantibodies may drive the worsening of the disease. It has long been known that defective engulfment or processing of dying cells causes the development of autoimmune diseases (Boada-Romero et al., 2020; Cohen et al., 2002; Miyaniishi et al., 2007; Peng and Elkon, 2011; Rodriguez-Manzanet et al., 2010). In light of our findings, perhaps defective clearance of AC caused by SARS-CoV-2 infection and SARS-CoV-2-loaded ACs also contributes to COVID-19-associated autoimmunity.

As it becomes clear that worsening of COVID-19 occurs because of immune dysfunction, antivirals, and other therapeutic efforts to limit viral replication may fail to benefit critically ill patients. In those patients, successful therapeutic strategies may rely on targeting dysregulated components of the host response to limit damage to the host, thus promoting disease tolerance and stimulating a resolutive response that restores homeostasis. In this context, our study provides important insights into the mechanisms driving the pathophysiology of COVID-19 that can be explored in the design of therapeutic approaches toward harnessing innate immune responses and macrophage function during the evolution of SARS-CoV-2 infection.

### Materials and methods

| Key resources table |
|---------------------|
| Reagent type (species) or resource | Designation | Source or reference | Identifiers | Additional information |
| Antibody | anti-Sars-CoV-2 Spike (rabbit polyclonal) | Abcam | Cat: #ab272504 RRID: AB_2847845 | WB and FACS (1:1000); Immunofluorescence (1:1000) |
| Antibody | anti-CD11b+CD11 c (mouse monoclonal) | Abcam | Cat: #ab1211 RRID: AB_442947 | Immunofluorescence (1:300) |
| Antibody | anti-human CD68 (mouse monoclonal) | Abcam | Cat: #ab955 RRID: AB_307338 | Immunofluorescence (1:100) |
| Antibody | anti-CD206-FITC (mouse monoclonal) | BD Biosciences | Cat: #551135 RRID: AB_394065 | FACS (1:200) |
| Antibody | anti-caspase-3 (rabbit polyclonal) | Cell Signaling | Cat: #9662 RRID: AB_331439 | WB (1:1000) |
| Antibody | anti-cleaved caspase-3 (rabbit monoclonal) | Cell Signaling | Cat: #9664 RRID: AB_10694088 | WB and Immunofluorescence (1:1000); FACS (1:200) |
| Antibody | anti-caspase-8 (rabbit monoclonal) | Cell Signaling | Cat: #4790 RRID: AB_10545768 | WB (1:1000) |
| Antibody | anti-cleaved caspase-8 (rabbit monoclonal) | Cell Signaling | Cat: #9496 RRID: AB_561381 | WB (1:1000) |
| Antibody | anti-βactin HRP conjugate (mouse monoclonal) | Cell Signaling | Cat: #12262 RRID: AB_2566811 | WB (1:5000) |
| Antibody | anti-human CD36 (rabbit polyclonal) | Thermo Fisher Scientific | Cat: #PA5-81996 RRID: AB_2789157 | Immunofluorescence (1:100) |
| Antibody | anti-human Mertk (rabbit monoclonal) | Thermo Fisher Scientific | Cat: #MA5-31991 RRID: AB_2869285 | Immunofluorescence (1:150) |
| Antibody | anti-human cytokeratin 18 (rabbit polyclonal) | GeneTex | Cat: #GTX112977 RRID: AB_10719980 | Immunofluorescence (1:500) |

Continued on next page
### Reagent type (species) or resource

| Reagent type (species) or resource | Designation | Source or reference | Identifiers | Additional information |
|-----------------------------------|-------------|---------------------|-------------|------------------------|
| Antibody                          | anti-dsRNA J2 (mouse monoclonal) | SCICONS English & Scientific Consulting Kft | Cat: #10010200 RRID: AB_2651015 | Immunofluorescence (1:1000) |
| Antibody                          | donkey anti-rabbit IgG HRP (donkey polyclonal) | Jackson ImmunoResearch | Cat: #711-036-152 RRID: AB_2340590 | WB (1:5000) |
| Antibody                          | Alexa-594 goat-anti mouse IgG (goat polyclonal) | Thermo Fisher Scientific | Cat: #A11005 RRID: AB_2534073 | Immunofluorescence (1:500) |
| Antibody                          | Alexa-488 donkey-anti rabbit IgG (donkey polyclonal) | Thermo Fisher Scientific | Cat: #A21206 RRID: AB_2535792 | FACS (1:2500) and Immunofluorescence (1:500) |
| Antibody                          | Alexa-594 goat-anti rabbit IgG (goat polyclonal) | Thermo Fisher Scientific | Cat: #A11012 RRID: AB_141359 | Immunofluorescence (1:500 or 1:1000) |
| Antibody                          | Alexa-488 F(ab)'2 goat-anti mouse IgG (goat polyclonal) | Thermo Fisher Scientific | Cat: #A11017 RRID: AB_2536084 | Immunofluorescence (1:500) |
| Antibody                          | Alexa-647 donkey-anti mouse IgG (donkey polyclonal) | Thermo Fisher Scientific | Cat: #A31571 RRID: AB_162542 | Immunofluorescence (1:500 or 1:1000) |
| Antibody                          | Alexa-647 goat anti-rabbit IgG (goat polyclonal) | Thermo Fisher Scientific | Cat: #A21244 RRID: AB_2535812 | Immunofluorescence (1:500) |
| Cell line (Homo sapiens)          | Calu-3      | BCRJ #0264 ATCC #HTB-55 |             |                        |
| Cell line (H. sapiens)            | Jurkat E6-1 | BCRJ #0125 ATCC #TIB-152 |             |                        |
| Cell line (H. sapiens)            | THP-1       | Dario Zamboni’s lab ATCC: #TIB-202 |             |                        |
| Cell line (Cercopithecus aethiops) | Vero CCL81  | Dario Zamboni’s lab ATCC: #CCL-81 |             |                        |
| Strain, strain background (human) | SARS-CoV-2  | Brazil/SPBR-02/2020 |             |                        |
| Strain, strain background (human) | Coxsackievirus B5 | Roger M. Loria’s lab |             |                        |
| Chemical compound, drug          | FITC Annexin V | BD Biosciences | Cat: #556,420 | FACS (1:200) |
| Chemical compound, drug          | Purified Recombinant Annexin V | BD Biosciences | Cat: #556,416 |                        |
| Chemical compound, drug          | Zombie NIR Fixable Viability | Biolegend | Cat: #423,106 | FACS (1:400) |
| Chemical compound, drug          | Zombie Violet Fixable Viability Kit | Biolegend | Cat: #423,114 | FACS (1:400) |
| Chemical compound, drug          | Remdesivir | BOC Sciences | Cat: #1809249-37-3 |                        |
| Chemical compound, drug          | phorbol 12-myristate 13-acetate (PMA) | InvivoGen | Cat: #T1rl-pma |                        |
| Chemical compound, drug          | Annexin V MicroBeads | Miltenyi Biotec | Cat: #130-090-201 |                        |
| Chemical compound, drug          | Z-VDACMK | Selleckchem | Cat: #S7023 |                        |
| Chemical compound, drug          | Glycin | Sigma | Cat: #G7126 |                        |
| Chemical compound, drug          | complete, Mini Protease Inhibitor Cocktail | Sigma | Cat: #11836153001 |                        |
| Chemical compound, drug          | Cytochalasin D | Sigma | Cat: #C8273 |                        |
| Chemical compound, drug          | CellTrace CFSE Cell Proliferation Kit | Thermo Fisher Scientific | Cat: #C34555 |                        |
| Chemical compound, drug          | CellTrace Far Red Cell Proliferation Kit | Thermo Fisher Scientific | Cat: #C34564 |                        |
| Chemical compound, drug          | CellTrace Violet Cell Proliferation Kit | Thermo Fisher Scientific | Cat: #C34557 |                        |
| Chemical compound, drug          | pHrodo Red AM Intracellular pH Indicator | Thermo Fisher Scientific | Cat: #P35372 |                        |
| Chemical compound, drug          | Hoechst 33,342 | Thermo Fisher Scientific | Cat: #H3570 |                        |
| Commercial assay or kit          | BD Cytofix/Cytoperm Fixation/ Permeabilization Kit | BD Biosciences | Cat: #554,715 |                        |
| Commercial assay or kit          | CytoTox 96 Non-Radioactive Cytotoxicity Assay | BD Biosciences | Cat: #G1780 |                        |

Continued on next page
### Study approval
The procedures followed in the study were approved by the Research Ethics Committee of Hospital das Clínicas de Ribeirão Preto (CEP-FMRP/USP) and by the National Ethics Committee, Brazil Comissão Nacional de Ética em Pesquisa, protocols 30248420.9.0000.5440 and 39722020.9.0000.5440. Written informed consent was obtained from recruited donors.

### Isolation of human peripheral blood mononuclear cells, monocyte seeding, and macrophage differentiation
Peripheral blood mononuclear cells (PBMC) from healthy donors were isolated from peripheral blood. The samples were centrifuged at 400 g for 10 min at room temperature (RT), the plasma was discarded, and the cellular portion was diluted in phosphate-buffered saline (PBS). PBMC were isolated by density-gradient centrifugation using Histopaque-1077 (Sigma-Aldrich). The collected PBMC fraction was treated with ACK lysis buffer to lyse erythrocytes and washed twice with PBS. For macrophages differentiation, monocytes were cultivated for 7 days in RPMI 1640 media supplemented with penicillin (10,000 U/mL, GIBCO), streptomycin (10,000 μg/mL, GIBCO), 1% glutamine (GIBCO), and 10% heat-inactivated human serum (Sigma Aldrich) at 37°C in a 5% CO₂ atmosphere.

### Cell lines
Calu-3 and Jurkat cells were originally from (ATCC) and purchased from Banco de Células do Rio de Janeiro (BCRJ). Vero CCL81 and THP-1 cells were from Dario Zamboni’s lab. No authentication method was used. Calu-3 and Vero CCL81 cells were maintained in Dulbecco’s Modified Eagle Media (DMEM) with 4.5 g/L glucose (GIBCO) supplemented with penicillin (10,000 U/mL), streptomycin (10,000 μg/mL), and 10% heat-inactivated fetal bovine serum (FBS, GIBCO) (DMEMc) at 37°C in a 5% CO₂ atmosphere. Jurkat cells and THP-1 cells were maintained in RPMI1640 media supplemented with penicillin (10,000 U/mL), streptomycin (10,000 μg/mL), 1% glutamine, and 10% FBS (RPMIc) at 37°C in a 5% CO₂ atmosphere.

THP-1-derived macrophages were obtained by treatment with phorbol 12-myristate 13-acetate (PMA, 50 ng/mL, Sigma-Aldrich) for 24 hr, followed by media replenishment with fresh RPMIc and another 24 hr incubation period before stimulation.

Cell lines were routinely screened by PCR for mycoplasma contamination, and all cell lines tested negative.
Viral stock
The SARS-CoV-2 strain (Brazil/SPBR-02/2020) was isolated from the first Brazilian case of COVID-19. The viral stock was produced in a monolayer of Vero CCL81 cells expressing ACE2 (Rodrigues et al., 2021), maintained in serum-free DMEM at 37°C in a 5% CO₂ atmosphere. Coxsackievirus B5 (Coxsackie) was originally shared by Dr Roger M Loria (Virginia Commonwealth University, Richmond, Virginia, USA) (Gomes et al., 2010). The viral stock was produced in a monolayer of HeLa cells maintained in DMEM supplemented with 2% FBS at 37°C and 5% CO₂. Viral stocks were propagated under BSL3 conditions and stored at –80°C. Viral loads were estimated by titration in Vero CCL81 cells seeded onto 96-well plates and standard limiting dilution to confirm the 50% tissue culture infectious dose.

Infection and UV irradiation of epithelial cell lines
Cell monolayers were rinsed with PBS, replenished with a thin layer of serum-free media, and infection with a freshly thawed virus aliquot at a multiplicity of infection (MOI) of approximately 0.05 was carried out for 1 hr at 37°C and 5% CO₂ for viral adsorption. The cells were then topped with fresh media and incubated for 48 hr. Sterile AC (UV-AC) were generated by exposure to UV-C radiation (Calu-3 cells at 500 mJ/cm² and Vero CCL81 cells at 350 mJ/cm²) in a UV crosslinker (Fisher Scientific), followed by 6 hr incubation in DMEMc at 37°C and 5% CO₂.

Cell death assays
Cells were collected 48 hr post-infection or 6 hr post-irradiation, spun at 300 g for 5 min, washed with PBS, and resuspended in the appropriate buffer before analysis.

For the analysis of caspase-8 and caspase-3 cleavage, 2.0 × 10⁶ Vero CCL81 and Calu-3 cells stimulated as described were lysed in radio immuno-precipitation assay (RIPA) buffer (10 mM Tris-HCl, pH 7.4, 1 mM EDTA, 150 mM NaCl, 1% Nonidet P-40, 1% deoxycholate, and 0.1% SDS) supplemented with protease inhibitor cocktail (Sigma). Preleared lysates were quantified by Bradford assay, boiled in Laemmli buffer, resolved by SDS-PAGE, and transferred to poly(vinylidene fluoride) membranes. Rabbit anti-cleaved caspase-3/caspase-3/cleaved caspase-8 (all from Cell Signaling), rabbit anti-SARS-CoV-2 Spike (Abcam), HRP-conjugated goat anti-actin (Cell Signaling), and species-specific horseradish-conjugated secondary antibodies were used for antigen detection.

For the analysis of cleaved caspase-3 by flow cytometry, infection of Calu-3 cells was carried out in the presence of Z-VAD-FMK (Selleckchem) at 20 μM, or mock treatment with vehicle (DMSO), added to cell cultures after virus adsorption. 10⁵ collected cells were washed with PBS, and fixation, permeabilization, and staining were carried out using BD Cytofix/Cytoperm Fixation/Permeabilization Kit (BD Biosciences), following the manufacturer’s instructions. Samples were incubated with rat serum (1:400) for 5 min at RT followed and immunolabeling of intracellular active caspase-3 was performed with anti-cleaved caspase-3 (Cell Signaling, 1:400) and secondary donkey anti-rabbit IgG conjugated to Alexa Fluor 488 (Thermo Fisher Scientific, 1:2,500). Sample acquisitions were performed in a FACSVerse (BD Biosciences) flow cytometer and data processing was performed using FlowJo_V10 software (BD Biosciences).

Cell death profiling in infected or UV-irradiated Vero CCL81 cells was performed with a viability dye (Zombie NIR Fixable Viability Dye, Biolegend, 1:400) and annexin V (FITC annexin V, BD Biosciences, 1:200) co-labeling. Labeling of 1.0 × 10⁶ cells with Zombie NIR was carried out for 10 min on ice, followed by annexin V labeling for 15 min on ice with cells resuspended annexin V binding buffer (0.01 M HEPES, 0.14 M NaCl, 2.5 mM CaCl₂, pH 7.4). Sample acquisitions were performed in a BD FACSMelody (BD Biosciences) cell sorter and data processing was performed using FlowJo_V10 software (BD Biosciences).

To determine LDH release, infection or UV irradiation of 2.0 × 10⁵ Vero CCL18 cells was carried out in DMEMc without Phenol Red. LDH release was measured in the culture supernatants using the CytoTox 96 non-radioactive cytotoxicity assay (Promega), following the manufacturer’s instructions.

Isolation of apoptotic cells
AC were generated from SARS-CoV-2-infected (CoV2-AC) or UV-irradiated (UV-AC) Vero CCL81 and Calu-3 cells, or Coxsackievirus B5-infected Vero CCL81 cells (Coxsackie-AC). At the established time points, the supernatants were collected and temporarily stored for further processing. Then, a
suspension containing CoV2-AC, Coxsackie-AC, or UV-AC was obtained by carefully pipetting fresh media up and down the plate surface and collecting loosely attached cells. Following spin at 300 g for 5 min, pelleted AC were washed with PBS, resuspended in RPMIC, and counted prior to incubation with macrophages. Enrichment in AC was confirmed by annexin V staining and flow cytometry.

To sort CoV2-AC populations, annexin V+ cells were pre-enriched using magnetic separation (Annexin V MicroBead Kit, Miltenyi Biotec) following the manufacturer’s instructions. Then cells were labeled with Zombie NIR and annexin V-FITC, as described above, and cell sorting was performed in a BD FACSMelody (BD Biosciences) cell sorter. Isolated CoV2-AC were washed in PBS, resuspended in fresh RPMIC, and counted prior to incubation with macrophages.

For virus inactivation, isolated CoV2-AC suspension were transferred to a culture dished and placed onto tissue culture hood surface with an open lid for 20 min with the UV-C lamp on. Virus inactivation was confirmed by TCID_{50}, as described below. Alternatively, isolated AC were fixed with 2% PFA in PBS for 10 min and washed twice with PBS before adding to macrophage cultures.

To prepare the cell-free conditioned supernatants of the infected AC (CoV2-AC Sup), collected supernatants were spun at 300 g for 5 min to remove cellular debris; the resulting supernatant was filtered using a 0.22 µm syringe filter and immediately used for macrophage stimulation. The volume of CoV2-AC Sup used to stimulate macrophages was normalized to the amount of collected AC.

**TCID_{50} quantification of viable viral particles**

1.0 × 10^6 isolated CoV2-AC and their equivalent purified conditioned supernatants, obtained as described above, were lysed by snap freeze-and-thaw. To estimate viral load in AC isolated by annexin V labeling, all infected cells were collected, followed by magnetic separation with annexin V microbeads (Miltenyi Biotec) according to the manufacturer’s protocol. 1.0 × 10^6 pre-sorted cells and annexin+ cells were lysed by freeze-and-thaw for quantification. Viral loads were estimated by titration in Vero CCL81 cells seeded onto 96-well plates and expressed as 50% tissue culture infectious dose (TCID_{50}). Quantification was performed with the Reed-Muench method and plotted as TCID_{50} units per mL (Reed and Muench, 1938).

**In vitro assays with THP-1- and PBMC-derived macrophages**

1.0 × 10^6 THP-1- and PBMC-derived macrophages seeded on 24-well tissue culture plates were rinsed with warm PBS before stimulation. Macrophage cultures were then topped with UV-AC, CoV2-AC, or Coxsackie-AC resuspended in the appropriate serum-containing macrophage media at a 1:1 ratio. Macrophage cultures were rinsed out 2 hr after incubation to remove unbound AC and topped with fresh media. At the indicated time points, cell supernatants were collected, and macrophages were rinsed at least twice with warm PBS to remove cell debris before proceeding to further analysis. To block AC ligation and efferocytosis, CoV2-AC were pre-incubated with 0.1 or 0.01 µg/mL of annexin V (BD Biosciences), and macrophage stimulation was carried out in RPMIC supplemented with Ca^{2+}.

To block AC internalization, macrophages were pre-treated for 30 min, and incubation was carried out in the presence of Cytochalasin D (10 µM, Sigma). Where indicated, macrophages were topped with fresh media containing Remdesivir (20 µM, BOC Sciences) after removal of unbound AC.

For stimulation with conditioned supernatants, CoV2-AC-Sup were added directly to macrophage cultures and topped with fresh media for volume adjustment. Infection with SARS-CoV-2 or Coxsackievirus was carried out with virus adsorption at MOI 0.1 in serum-free media for 1 hr before topping with fresh serum-containing media.

For gene expression analysis by RT-qPCR, rinsed macrophage cultures were lysed in Trizol (Thermo Scientific) and immediately frozen at –80°C.

To estimate CD206 surface expression, rinsed macrophages were removed with a cell scraper, spun at 300 g for 5 min, washed with PBS, followed by incubation with rat serum (1:400) for 5 min at RT and cell surface staining for 15 min at 4°C. Cells were labeled with Zombie Violet Fixable Viability Kit (Biolegend) and anti-CD206-FITC antibody (clone 19.2, BD Biosciences). The cells were then fixed with 2% PFA for 10 min and washed before flow cytometric analyses in a FACSVerse (BD Biosciences) flow cytometer and data processing was performed using FlowJo_V10 software (BD Biosciences).

For immunofluorescence imaging of efferocytosis in vitro, human monocyte-derived macrophages seeded onto 13 mm round coverslips were incubated with UV-AC or CoV2-AC labeled with 5 µM CellTrace CFSE dye (Thermo Scientific) for 2 hr. After rinsing out non-engulfed AC, macrophages
were fixed for 20 min with PBS 2% PFA at RT. Cells were then permeabilized with 0.1% Triton-X-100 in PBS for 10 min at RT. Next, cells were rinsed twice in PBS and incubated with PBS 1% bovine serum albumin (BSA) and 5 µg/mL normal donkey IgG (Jackson ImmunoResearch) for 45 min RT prior to overnight (ON) incubation at 4°C with primary antibodies: rabbit polyclonal anti-SARS-CoV-2 Spike antibody (Abcam, 1:1000) and mouse mAb anti-rat CD11b (Abcam, 1:300) diluted in PBS containing 1% BSA. Next, cells were rinsed thoroughly in PBS and incubated for 30 min at RT with the secondary antibodies diluted in PBS: Alexa-594 goat-anti rabbit IgG (1:1000; Thermo Scientific) and Alexa-647 donkey-anti mouse IgG (1:1000; Thermo Scientific). Cell nuclei were stained with Hoechst 33,342.

Samples were imaged using a Zeiss LSM 780 laser scanning confocal microscope (Carl Zeiss), post-processed for brightness and contrast adjustment with ImageJ image processing package (NIH), and layouts were built on Adobe Photoshop.

For the engulfment assays by flow cytometry, macrophages were labeled with 5 µM CellTrace Violet dye (CTV, Thermo Scientific), according to the manufacturer’s recommendations. CellTrace Violet (CTV)-labeled macrophages were stimulated with UV-AC or CoV2-AC previously stained with 1 µM CellTrace Far Red dye (CTFR, Thermo Scientific) or 5 µM CellTrace CFSE dye, as described in the legend of the figures. Following the removal of unbound AC, macrophages were collected with a cell scraper, fixed with 2% PFA for 10 min, and washed before proceeding with the acquisition by flow cytometry. For the two-round efferocytosis assay, first-round UV-AC and CoV2-AC were labeled with a pH indicator fluorogenic intracellular probe (pHRodo Red AM Intracellular pH Indicator - Thermo Scientific). Second-round apoptotic Jurkat cells (UV-Jurkat) were generated by labeling with 1 µM CTFR and UV-C irradiation at 20 mJ/cm², followed by incubation at 37°C and 5% CO₂ for 6 hr. CTV-labeled THP-1 cells were incubated with pHrodo-UV-AC or pHrodo-CoV2-AC for 18 hr at a 1:1 ratio. Cells were then rinsed with PBS, and CTV-labeled UV-Jurkat cells were added to the culture at a 1:1 ratio for 2 hr. Macrophage cultures were collected with a cell scraper, washed, fixed with 2% PFA for 10 min, and washed before proceeding with the acquisition by flow cytometry. Flow cytometric acquisition was performed in a FACSVerse (BD Biosciences) flow cytometer and data processing was performed using FlowJo_V10 software (BD Biosciences).

**Cytokine quantification**

IL-6 and IL-1β cytokine levels in macrophage supernatants were evaluated by ELISA assay (R&D Systems) or cytometric bead array (CBA, BD Biosciences), as indicated in the legend of the figures, following the manufacturers’ recommendations.

**RNA isolation and gene expression analyses**

Total RNA extraction for human monocyte- or THP-1-derived macrophages stimulated in vitro was performed using Directzol RNA miniPrep Kit (Zymo Research), following the manufacturer’s recommendations. Reverse transcriptase was performed using Moloney Murine Leukemia Virus reverse transcriptase (Thermo Scientific) according to the manufacturer’s recommendations.

Gene expression RT-qPCR was performed using SybrGreen Master Mix (Applied Biosystems). RT-qPCR was performed in fast mode, following the manufacturer’s recommendations. The evaluation of each gene expression was determined by the comparative CT method. Primer sequences used were:

| Gene   | 5' Forward                  | 3' Reverse                  |
|--------|-----------------------------|-----------------------------|
| CCL18  | CTCTGTGCTGCTTGTTACCT        | CTTGGTGGAGGAGATGACACCT      |
| CD163  | GCGGGAGGAGTGGAAAGTAAGAGA   | GTTCAAAATACAGAGAGGCGCT      |
| CD36   | GGAAAGGTCTACCTGGAGATG       | TGCAATTACCTTGTTCTTA         |
| GAPDH  | GTCTCTGCTGCTGCTGAAC        | ACCACCCGGTGGCTGCTACCCC     |
| IL6    | GGTACATCCTGCTGACGCTCT      | GTGCCCTTTTGGCTTTCTC         |
| ITGB5  | AACCAGAGGCTGTTACCAAGAA     | AGGAGAAGTTGTCGACTCA        |
| MERTK  | CTCTGGCCTGCTGCTGCTACCT     | AGGCTGGGTTGACAA           |

Continued on next page
Histological analysis

Ultrasound-guided minimally invasive autopsies for COVID-19 deceased patients were approved by the Research Ethics Committee of Hospital das Clínicas de Ribeirão Preto (CEP, protocol no. 4.089.567). Supplementary file 2 describes clinical, laboratory, and treatment records of COVID-19 patients. Non-neoplastic sections of lung parenchyma were obtained from lobectomies for lung cancer as a control group (Rodrigues et al., 2021). Paraffin sections from lungs were collected and processed as previously described (Rodrigues et al., 2021). Sections were rinsed in PBS, and the antigen retrieval was performed by incubation of samples with 0.1% trypsin (ThermoFisher Scientific) in PBS at 37°C for 15 min. Next, sections were rinsed and incubated with Image-IT FX Signal Enhancer (ThermoFisher Scientific) for 30 min at RT. Sections were then rinsed in PBS and incubated for 45 min at RT in PBS containing 0.5% BSA and 5 μg/mL normal donkey IgG (Jackson ImmunoResearch). For analysis of active caspase-3, lung sections were labeled with primary antibodies diluted in PBS and incubated overnight at 4°C: rabbit polyclonal anti-human cleaved caspase-3 (Asp175) (Cell Signaling; 1:1000) and mouse anti-dsRNA (SCICONS; 1:1000). Then, sections were rinsed thoroughly in PBS and incubated for 45 min at RT with the secondary antibodies: Alexa 594 goat anti-rabbit IgG (1:500; Thermo Fisher Scientific) and Alexa 488 goat anti-mouse IgG (ab)′2 (1:500; Thermo Fisher Scientific) diluted in PBS. Cell nuclei were stained with Hoechst 33,342. Cells were then rinsed, and coverslips mounted on glass slides with Fluoromount-G (Invitrogen). For in situ efferocytosis analysis, lung sections were labeled with primary antibodies mouse mAb anti-human CD68 (Abcam; 1:100), rabbit mAb anti-human cytokeratin 18 (GeneTex, 1:500) diluted in PBS and incubated overnight at 4°C. Then, sections were rinsed thoroughly in PBS and incubated for 45 min at RT with the secondary antibodies F(ab)′2 goat anti-mouse IgG conjugated to Alexa 488 (1:500; Thermo Scientific) and goat anti-rabbit IgG conjugated to Alexa 647 (1:500; Thermo Scientific). Next, sections were rinsed in PBS and incubated overnight at 4°C with rabbit polyclonal anti-SARS-CoV-2 Spike (Abcam; 1:1000) previously conjugated to Alexa 568, according to the manufacturer’s instructions (Zenon Alexa Fluor 568 Rabbit IgG Labeling Kit, Thermo Scientific). Sections were then rinsed in PBS and incubated for 15 min at RT with Hoechst 33,342 (Invitrogen), rinsed thoroughly, and mounted on glass slides with Fluoromount-G (Invitrogen). Samples from Cl-caspase-3 and in situ efferocytosis experiments were imaged using an ECLIPSE Ti2 Series microscope equipped with a DS-Qi2 camera (Nikon Instruments Inc). Analysis was performed using NIS Elements (Nikon Instruments Inc), wherein mean intensity fluorescence for Cl-caspase-3 was determined for randomly selected epithelial cells. Representative images were postprocessed for brightness and contrast adjustment with ImageJ image processing package (NIH) and layouts were built on Adobe Photoshop.

For CD36 or MERTK expression analysis, lung sections were labeled with the primary antibodies diluted in PBS and incubated overnight at 4°C: rabbit polyclonal anti-human CD36 (PA5-81996; 1:100 ThermoFisher Scientific) or rabbit mAb anti-human MERTK (Clone SR29-07; 1:150; ThermoFisher Scientific) and mouse mAb anti-human calprotectin (Clone MAC387; MA1-81381; 1:100; ThermoFisher Scientific). Then, sections were rinsed thoroughly in PBS and incubated for 45 min at RT with the secondary antibodies Alexa 488 donkey anti-rabbit IgG (1:500; Thermo Fisher Scientific) and Alexa 594 donkey anti-rabbit IgG (Thermo Scientific) diluted in PBS. Sections were then rinsed, and coverslips mounted with DAPI Fluoromount-G. Samples were imaged using a Olympus BX61 Fluorescence Motorized Slide Scanner Microscope Pred VS120 (Olympus). Analysis was performed using ImageJ image processing package (NIH), wherein mean intensity fluorescence for CD36 and MERTK
was determined for randomly selected S1009+ cells. Representative images were postprocessed for brightness and contrast adjustment with ImageJ image processing package (NIH) and layouts were built on Adobe Photoshop.

Re-analysis of scRNA-seq data
We re-analyzed single-cell transcriptomic data from BAL fluid from patients with varying severity of COVID-19 disease and their respective healthy controls (Liao et al., 2020). The dataset is publicly available at https://covid19-balf.cells.ucsc.edu/. Downloaded data was imported into R environment version v3.6.3. Differential expression analysis was conducted using FindMarkers function in Seurat using the Wilcoxon test to compare mild and severe COVID-19 patients with healthy individuals for each cluster previously identified by authors. Differentially expressed genes between mild/severe COVID-19 patients and controls for each cluster were identified considering genes expressed in at least 5% of cells and FDR <0.05 and |avg_logFC|>0.1. In addition, a differentially expressed gene list comparing infected (identified SARS-Cov-2 transcripts) against non-infected alveolar macrophages was obtained from supplemental materials from Ren et al., 2021. Gene set enrichment analysis (GSEA) was performed using ClusterProfiler and fgsea R packages (Korotkevich et al., 2016; Wu et al., 2021) for each differentially expressed gene or log2 fold change lists from Liao et al., 2020 and Ren et al., 2021 dataset. A custom gene set was also utilized as a reference for GSEA, incorporating GO:0006911, GO:0043277 GO terms, and additional efferocytic related genes from the literature (Penberthy and Ravichandran, 2016; Boada-Romero et al., 2020) (Supplementary file 1). Significantly enriched sets were identified considering terms with p-value <0.05.

Quantification and statistical analyses
Please refer to the legend of the figures for description of samples, sample sizes (biological replicates), and experimental replicates. No statistical tests were used to estimate sample size. Data were plotted and analyzed with GraphPad Prism 8.4.2 software (GraphPad Prism Software Inc, San Diego, CA). The statistical tests used are listed in the legend of the figures. For the in vitro assays, we used Student’s t-test to compare two experimental groups or ANOVA and multiple comparison correction to compare three or more experimental groups. For quantification of histological datasets, normality tests were performed, and samples with non-Gaussian distribution were analyzed applying the Mann–Whitney test.

Acknowledgements
The authors thank Dr Denise M da Fonseca, Msc Elizabete R Milani and Dr Roberta R C Rosales (FMRP-USP) for technical assistance. Funding: This work was supported by grants from Fundação de Amparo a Pesquisa do Estado de São Paulo (FAPESP) grants 2018/25559-4 and 2020/05288-6 (LDC); Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) grant 88887.507253/2020-00 (D S Z and LDC.); Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) grant 434538/2018-3 (LDC); D S, A C G S, T S R, M F R, E G F F, D L A T are supported by FAPESP fellowships.

Additional information

| Funding | Grant reference number | Author |
|---------|-------------------------|--------|
| Fundação de Amparo à Pesquisa do Estado de São Paulo | 2018/25559-4 | Larissa D Cunha |
| Fundação de Amparo à Pesquisa do Estado de São Paulo | 2020/05288-6 | Larissa D Cunha |
| Coordenação de Aperfeiçoamento de Pessoal de Nível Superior | 88887.507253/2020-00 | Dario S Zamboni |
Author contributions
Ana CG Salina, Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Validation, Visualization, Writing – original draft, Writing – review and editing; Douglas dos-Santos, Writing – review and editing, Conceptualization, Formal analysis, Investigation, Methodology, Validation, Writing – original draft; Tamara S Rodrigues, Conceptualization, Formal analysis, Investigation, Methodology, Writing – original draft; Marlon Fortes-Rocha, Edismauro G Freitas-Filho, Conceptualization, Formal analysis, Investigation, Writing – original draft; Daniel L Alzamora-Terrel, Conceptualization, Formal analysis, Writing – original draft; Icaro MS Castro, Formal analysis, Validation, Writing – original draft; Thais FC Fraga da Silva, Leticia Almeida, Adriene Y Ishimoto, Formal analysis, Writing – original draft; Thais FC Fraga da Silva, Leticia Almeida, Adriene Y Ishimoto, Formal analysis, Writing – original draft; Larissa D Cunha, Data curation, Funding acquisition, Investigation, Project administration, Resources, Supervision, Visualization, Writing – original draft

Author ORCIDs
Ana CG Salina http://orcid.org/0000-0003-3220-0413
Douglas dos-Santos http://orcid.org/0000-0002-7155-0443
Marlon Fortes-Rocha http://orcid.org/0000-0002-2055-2000
Edismauro G Freitas-Filho http://orcid.org/0000-0002-1910-1085
Thais M Lima http://orcid.org/0000-0002-5714-6057
Rodrigo L Assad http://orcid.org/0000-0002-8430-8357
Thiago M Cunha http://orcid.org/0000-0003-1084-0065
Helder I Nakaya http://orcid.org/0000-0001-5297-9108
Dario S Zamboni http://orcid.org/0000-0002-7856-7512
Larissa D Cunha http://orcid.org/0000-0002-1290-0263

Ethics
The procedures followed in the study were approved by the Research Ethics Committee of Hospital das Clínicas de Ribeirão Preto (CEP-FMRP/USP) and by the National Ethics Committee, Brazil Comissão Nacional de Ética em Pesquisa (CONEP), protocols 30248420.9.0000.5440 and 39722020.9.0000.5440. Written informed consent was obtained from recruited donors. Ultrasound-guided minimally invasive autopsies for COVID-19 deceased patients were approved by the Research Ethics Committee of Hospital das Clínicas de Ribeirão Preto (CEP, protocol no. 4.089.567).

Decision letter and Author response
Decision letter https://doi.org/10.7554/eLife.74443.sa1
Author response https://doi.org/10.7554/eLife.74443.sa2

Additional files
Supplementary files
• Supplementary file 1. Custom gene sets incorporating associated to efferocytic pathway and related to human diseases (related to Figure 5C).
• Supplementary file 2. Medical characteristics of COVID-19 patients.
Data availability

Source data files containing the numerical values for graphs depicting flow cytometry, ELISA, CBA, RT-qPCR, and imaging quantification data have been uploaded as csv files.

The following previously published datasets were used:

| Author(s)                                      | Year | Dataset title                                                                 | Dataset URL                                                                 | Database and Identifier       |
|------------------------------------------------|------|-------------------------------------------------------------------------------|----------------------------------------------------------------------------|--------------------------------|
| Liao M, Liu Y, Yuan J, Wen Y, Xu G, Zhao J, Cheng L, Li J, Wang X, Wang F, Liu L, Amit I, Zhang S, Zhang Z | 2020 | Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19 | https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE145926               | NCBI Gene Expression Omnibus, GSE145926 |
| Ren X, Wen W, Fan X, Hou W, Bin Su, Cai P, Li J, Liu Y, Tang F, Zhang F, Yang Y, Jiangping He, Ma W, Jingjing He, Wang P, Cao Q, Chen F, Chen Y, Cheng X, Deng G, Deng X, Ding W, Feng Y, Gan R, Guo C, Guo W, He S, Jiang C, Liang J, Li Y, Lin J, Ling Y, Liu H, Liu J, Liu N, Liu S-Q, Luo M, Ma Q, Song Q, Sun W, Wang G, Wang F, Wang Y, Wen X, Wu Q, Xu G, Xie X, Xiong X, Xing X, Xu H, Yin C, Yu D, Yu K, Yuan J, Zhang B, Zhang P, Zhang T, Zhao J, Peidong Zhao, Zhou J, Zhou W, Zhong S, Zhong X, Zhang S, Zhu L, Zhu P, Zou B, Zou J, Zuo Z, Bai F, Huang X, Zhou P, Jiang Q, Huang Z, Bei J-X, Wei L, Bian X-W, Liu X, Cheng T, Li X, Wang F-S, Wang H, Bing Su, Zheng Z, Qu K, Wang X, Chen J, Jin R, Zemin Z, Zhao P | 2021 | COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas | https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE158055 | NCBI Gene Expression Omnibus, GSE158055 |

References

A-Gonzalez N, Quintana JA, Garcia-Silva S, Mazariegos M, Gonzalez de la Aleja A, Nicolás-Ávila JA, Walter W, Adrover JM, Crainiciuc G, Kuchroo VK, Rothlin CV, Peinado H, Castrillo A, Ricote M, Hidalgo A. 2017. Phagocytosis imprints heterogeneity in tissue-resident macrophages. *The Journal of Experimental Medicine* 214:1281–1296. DOI: https://doi.org/10.1084/jem.20161375, PMID: 28432199

Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y, Dorgham K, Philippot Q, Rosain J, Béziat V, Manry J, Shaw E, Haljasmägi L, Peterson P, Lorenzo L, Bizien L, Trouillot-Assant S, Dobbs K, de Jesus AA, Belot A, et al. 2020. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. *Science* 370:eabd4585. DOI: https://doi.org/10.1126/science.abd4585, PMID: 32972996

Blanco-Melo D, Nilsson-Payant BE, Liu W-C, Uhl S, Hoagland D, Møller R, Jordan TX, Oishi K, Panis M, Sachs D, Wang TT, Schwartz RE, Lim JK, Albrecht RA, tenOever BR. 2020. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. *Cell* 181:1036-1045.. DOI: https://doi.org/10.1016/j.cell.2020.04.026, PMID: 32416070

Boada-Romero E, Martinez J, Heckmann BL, Green DR. 2020. The clearance of dead cells by efferocytosis. *Nature Reviews. Molecular Cell Biology* 21:398–414. DOI: https://doi.org/10.1038/s41580-020-0232-1, PMID: 32251387
Bosurgi L, Cao YG, Cabeza-Cabrerizo M, Tucci A, Hughes LD, Kong Y, Weinstein JS, Licona-Limon P, Schmid ET, Pelorosso F, Gagliani N, Craft JE, Flavell RA, Ghosh S, Rothlin CV. 2017. Macrophage function in tissue repair and remodeling requires IL-4 or IL-13 with apoptotic cells. Science 356:1072–1076. DOI: https://doi.org/10.1126/science.aai8132, PMID: 28495875

Chan JFW, Zhang AJ, Yuan S, Poon VKM, Chan CCS, Lee ACY, Chan WM, Fan Z, Tsoi HW, Wen L, Liang R, Cao J, Chen Y, Tang K, Luo C, Cai JP, Kok KH, Chu H, Chan KH, Sridhar S, et al. 2020. Simulation of the Clinical and Pathological Manifestations of Coronavirus Disease 2019 (COVID-19) in a Golden Syrian Hamster Model: Implications for Disease Pathogenesis and Transmissibility. Clinical Infectious Diseases 71:2428–2446. DOI: https://doi.org/10.1093/cid/ciaa335, PMID: 32215622

Chan EY, Tan CM, Kuy O, Duan Q, Wang Z, Meirellas GV, Clark NR, Ma’ayan A. 2013. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics 14:128. DOI: https://doi.org/10.1186/1471-2105-14-128, PMID: 23586463

Chen L, Long X, Xu Q, Tan J, Wang G, Cao Y, Wei J, Luo H, Zhu H, Huang L, Meng F, Huang L, Wang N, Zhou X, Zhao L, Chen X, Mao Z, Chen C, Li Z, Sun Z, et al. 2020. Elevated serum levels of S100A8/A9 and HMGB1 at hospital admission are correlated with inferior clinical outcomes in COVID-19 patients. Cellular & Molecular Immunology 17:992–994. DOI: https://doi.org/10.1038/s41423-020-0492-x, PMID: 32620787

Chu H, Chan JFW, Yuen TTT, Shuai H, Yuan S, Wang Y, Hu B, Yip CYY, Tsang JOL, Huang X, Chai Y, Yang D, Hou Y, Chik KK, Zhang X, Fung AYF, Tsoi HW, Cai JP, Chan WM, Ip JD, et al. 2020. Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study. The Lancet. Microbe 1:e16–e23. DOI: https://doi.org/10.1016/S2666-5247(20)30004-5, PMID: 32835326

Chu H, Shuai H, Hou Y, Zhang X, Wen L, Huang X, Hu B, Yang D, Wang Y, Yoon C, Wong BHY, Li C, Zhao X, Poon VKM, Cai JP, Wong KH, Yeung ML, Zhou J, Aziz S, et al. 2021. Targeting highly pathogenic coronavirus-induced apoptosis reduces viral pathogenesis and disease severity. Science Advances 7:eabd8577. DOI: https://doi.org/10.1126/sciadv.abd8577, PMID: 34134991

Cohen PL, Caricchio R, Abraham V, Camenisch TD, Journe JC, Ruebey RAS, Earp HS, Matsuhashi G, Reap EA. 2002. Delayed apoptotic cell clearance and lupus-like autoimmunity in mice lacking the c-mer membrane tyrosine kinase. The Journal of Experimental Medicine 196:135–140. DOI: https://doi.org/10.1084/jem.20012094, PMID: 12093878

Doran AC, Yurdagul A, Tabas I. 2020. Efferocytosis in health and disease. Nature Reviews. Immunology 20:254–267. DOI: https://doi.org/10.1038/s41577-019-0240-6, PMID: 31822793

Evavold CL, Ruan J, Tan Y, Xia S, Wu H, Kagan JC. 2018. The Pore-Forming Protein Gasdermin D Regulates Interleukin-1 Secretion from Living Macrophages. Immunity 48:35–45. DOI: https://doi.org/10.1016/j.immuni.2017.11.013, PMID: 29195811

Fadok VA, Voelker DR, Campbell PA, Cohen JJ, Bratton DL, Henson PM. 1992. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. Journal of Immunology 148:2207–2216 PMID: 15451262

Frank A, Rauen U, de Groot H. 2000. Protection by glycine against hypoxic injury of rat hepatocytes: inhibition of ion fluxes through nonspecific leaks. Journal of Hepatology 32:58–66. DOI: https://doi.org/10.1016/s0168-8278(00)80190-7, PMID: 10673068

Gomes R, Guerra-Sá R, Arruda E. 2010. Coxsackievirus B5 induced apoptosis of HeLa cells: effects on p53 and SUMO. Virology 396:256–263. DOI: https://doi.org/10.1016/j.virol.2009.10.005, PMID: 19906394

Han Y, Zhang H, Mu S, Wei W, Jin C, Xue Y, Tong C, Zha Y, Song Z, Gu G. 2020. Lactate Dehydrogenase, a Risk Factor of Severe COVID-19 Patients. medRxiv. DOI: https://doi.org/10.1101/2020.03.24.20040162

Jamieson AM, Pasman L, Yu S, Gamradt P, Homer RJ, Decker T, Medzhitov R. 2013. Role of tissue protection in lethal respiratory viral-bacterial coinfection. Science 340:1230–1234. DOI: https://doi.org/10.1126.science.1233632, PMID: 23618765

Koretkevich G, Sukhov V, Budin N, Shpak B, Artyomov MN, Sergushichev A. 2016. Fast Gene Set Enrichment Analysis. bioRxiv. DOI: https://doi.org/10.1101/060012

Li S, Jiang L, Li X, Lin F, Wang Y, Li B, Jiang T, An W, Liu S, Liu H, Xu P, Zhao L, Zhang L, Mu J, Wang H, Kang J, Li Y, Huang L, Zhu C, Zhao S, et al. 2020a. Clinical and pathological investigation of patients with severe COVID-19. JCI Insight 5:138070. DOI: https://doi.org/10.1172/jci.insight.138070, PMID: 32427582

Li S, Zhang Y, Guan Z, Li H, Ye M, Chen X, Shen J, Zhou Y, Shi ZL, Zhou P, Peng K. 2020b. SARS-CoV-2 triggers inflammatory responses and cell death through caspase-8 activation. Signal Transduction and Targeted Therapy 5:3235. DOI: https://doi.org/10.1038/s41392-020-00334-0, PMID: 33037188

Liao M, Liu Y, Yuan J, Wen Y, Xu G, Zhao J, Cheng L, Li J, Wang X, Wang F, Liu L, Amti I, Zhang S, Zhang Z. 2020. Single-cell landscape of bronchoalveolar macrophages in patients with COVID-19. Nature Medicine 26:842–844. DOI: https://doi.org/10.1038/s41591-020-0901-9, PMID: 32398875

Lucas C, Wong P, Klein J, Castro TBR, Silva J, Sundaram M, Ellingson MK, Mao T, Oh JE, Israelow B, Takahashi T, Tokuyama M, Lu P, Venkataraman A, Park A, Mohanty S, Wang H, Wyllie AL, Vogels CBF, Earnest R, et al. 2020. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature 584:463–469. DOI: https://doi.org/10.1038/s41586-020-2588-y, PMID: 32717743

Martins R, Carlos AR, Braza F, Thompson JA, Bastos-Amador P, Ramos S, Soares MP. 2019. Disease Tolerance as an Inherent Component of Immunity. Annual Review of Immunology 37:405–437. DOI: https://doi.org/10.1146/annurev-immunol-042718-041739, PMID: 30673535

Miyaniishi M, Tada K, Koike M, Uchiyama Y, Kitamura T, Nagata S. 2007. Identification of Tim4 as a phosphatidylserine receptor. Nature 450:435–439. DOI: https://doi.org/10.1038/nature06307, PMID: 17960135
Morioka S, Perry JSA, Raymond MH, Medina CB, Zhi Y, Zhao L, Serbulea V, Onengut-Gumuscu S, Leitinger N, Kucenas S, Rathmell JC, Makowski L, Ravichandran KS. 2018. Efferocytosis induces a novel SLC program to promote glucose uptake and lactate release. *Nature* **563**:714–718. DOI: https://doi.org/10.1038/s41586-018-0735-5, PMID: 30464343

Mulay A, Konda B, Garcia G, Yao C, Beil S, Villalba JM, Koziol C, Sen C, Purkayastha A, Kolls JK, Pociask DA, Pessina P, de Aja JS, Garcia-de-Alba C, Kim CF, Gomperts B, Arumugawami V, Stripp BR. 2021. SARS-CoV-2 infection of primary human lung epithelium for COVID-19 modeling and drug discovery. *Cell Reports* **35**:e109055. DOI: https://doi.org/10.1016/j.celrep.2021.109055, PMID: 32905739

Murray PJ, Wynn TA. 2011. Protective and pathogenic functions of macrophage subsets. *Nature Reviews. Immunology* **11**:723–737. DOI: https://doi.org/10.1038/ni3073, PMID: 21997792

Nagata S. 2018. Apoptosis and Clearance of Apoptotic Cells. *Annual Review of Immunology* **36**:489–517. DOI: https://doi.org/10.1146/annurev-immunol-042617-050310, PMID: 29400998

Park D, Han CZ, Elliott MR, Kinchen JM, Trampont PC, Das S, Collins S, Lysiak JJ, Hoehn KL, Ravichandran KS. 2011. Continued clearance of apoptotic cells critically depends on the phagocyte Ucp2 protein. *Nature* **477**:220–224. DOI: https://doi.org/10.1038/nature10340, PMID: 21857682

Penberthy KK, Ravichandran KS. 2016. Apoptotic cell recognition receptors and scavenger receptors. *Immunological Reviews* **269**:44–59. DOI: https://doi.org/10.1111/imr.12376, PMID: 26683144

Peng Y, Elkson KB. 2011. Autoimmunity in MFG-E8-deficient mice is associated with altered trafficking and enhanced cross-presentation of apoptotic cell antigens. *The Journal of Clinical Investigation* **121**:2221–2241. DOI: https://doi.org/10.1172/JCI43254, PMID: 21537078

Perry JSA, Morioaka S, Medina CB, Iker Etchegaray J, Barron B, Raymond MH, Lucas CD, Onengut-Gumuscu S, Delpine E, Ravichandran KS. 2019. Interpreting an apoptotic corpse as anti-inflammatory involves a chloride sensing pathway. *Nature Cell Biology* **21**:1532–1543. DOI: https://doi.org/10.1038/s41556-019-0431-1, PMID: 31792383

Reed LJ, Muench H. 1938. A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS12. *American Journal of Epidemiology* **7**:493–497. DOI: https://doi.org/10.1093/oxfordjournals.aje.a118408

Ren Y, Shu T, Wu D, Mu J, Wang C, Huang M, Han Y, Zhang XY, Zhou W, Qiu Y, Zhou X. 2020. The ORF3a protein of SARS-CoV-2 induces apoptosis in cells. *Cellular & Molecular Immunology* **17**:881–883. DOI: https://doi.org/10.1038/s41423-020-0485-9, PMID: 32555321

Ren X, Wen W, Fan X, Hou W, Su B, Cai P, Li J, Liu Y, Tang F, Zhang F, Yang Y, He J, Ma W, He J, Wang P, Cao Q, Chen F, Chen Y, Cheng X, Deng G, et al. 2021. COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas. *Cell* **184**:1895-1913.. DOI: https://doi.org/10.1016/j.cell.2021.01.053, PMID: 33657410

Rodrigues TS, de Sá KSG, Ishimoto AC, Becerra A, Oliveira S, Almeida L, Gonçalves AP, Perucello DB, Wen W, Fan X, Hou W, Su B, Cai P, Li J, Liu Y, Tang F, Zhang F, Yang Y, He J, Ma W, He J, Wang P, Cao Q, Chen F, Chen Y, Cheng X, Deng G, et al. 2021. COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas. *Cell* **184**:1895-1913.. DOI: https://doi.org/10.1016/j.cell.2021.01.053, PMID: 33657410

Rodrigues-Manzanet R, Sanjuan MA, Wu HY, Quintana FJ, Xiao S, Anderson AC, Weiner HL, Green DR, Kuchroo VK. 2010. T and B cell hyperactivity and autoimmunity associated with nclassic-specific defects in apoptotic body clearance in TIM-4-deficient mice. *PNAS* **107**:8706–8711. DOI: https://doi.org/10.1073/pnas.0910359107, PMID: 20368430

Rothlin CV, Hille TD, Ghosh S. 2021. Determining the effector response to cell death. *Nature Reviews. Immunology* **21**:292–304. DOI: https://doi.org/10.1038/s41577-020-00456-0, PMID: 33188303

Schulte-Schrepping J, Reusch N, Paclick D, Baßler K, Schickleiser S, Zhang B, Kämmer B, Kramer T, Brumhard S, Bonaguro L, De Domenico E, Wendisch D, Grasshoff M, Kapellos TS, Beckstette M, Pecht T, Saglam A, Diether O, Mei HE, Schulz AR, et al. 2020. Severe COVID-19 Is Marked by a Deregulated Myeloid Cell Compartment. *Cell* **182**:1419–1440. DOI: https://doi.org/10.1016/j.cell.2020.08.002, PMID: 32810438

Siddiqi HK, Mehta MR. 2020. COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal. *The Journal of Heart and Lung Transplantation* **39**:405–407. DOI: https://doi.org/10.1016/j.healun.2020.03.012, PMID: 32362390

Silvin A, Chapuis N, Dunsmore G, Goubet AG, Dubuisson A, Derosa D, Hénon C, Kosmider O, Droin N, Rameau P, Catelan C, Alfaro A, Dussiau C, Friedrich C, Sourdeau E, Marin N, Szwobel TA, Cantin D, Mouthon L, et al. 2020. Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19. *Cell* **182**:1401–1410. DOI: https://doi.org/10.1016/j.cell.2020.08.002, PMID: 32810439

Stuart T, Butler A, Hoffman P, Hafemeister C, Papalexi E, Mauck WM, Hao Y, Stoeckius M, Sibert P, Satija R. 2019. Comprehensive Integration of Single-Cell Data. *Cell* **177**:1888–1902. DOI: https://doi.org/10.1016/j.cell.2019.05.031, PMID: 31178118

Trzebinski S, Jung S. 2020. Plasticity of monocyte development and monocyte fates. *Immunology Letters* **227**:66–78. DOI: https://doi.org/10.1016/j.imlet.2020.07.007, PMID: 32814154

Valle DMD, Kim-Schulz S, Huang HH, Beckmann ND, Nirenberg S, Wang B, Lavin Y, Swartz TH, Madduri D, Stock A, Maronn TU, Xie H, Patel M, Tubalbes K, Oekelen OV, Rahman A, Kovalchuk P, Alberga JA, Schadt E, Jagannath S, et al. 2020. An inflammatory cytokine signature predicts COVID-19 severity and survival. *Nature Medicine* **26**:1636–1643. DOI: https://doi.org/10.1038/s41591-020-1051-9

Veras FP, Ponteili MC, Silva CM, Toller-Kawahisa JE, de Lima M, Nascimento DC, Schneider AH, Caetité D, Tavares LA, Paiva IM, Rosales R, Colón D, Martins R, Castro IA, Almeida GM, Lopes MIF, Benatti MN, Bonjorno LP, Giannini MC, Luppino-Assad R, et al. 2020. SARS-CoV-2-triggered neutrophil extracellular traps

Salina, dos-Santos, Rodrigues et al. eLife 2022;11:e74443. DOI: https://doi.org/10.7554/eLife.74443 23 of 24
mediate COVID-19 pathology. *The Journal of Experimental Medicine* **217**:e20201129. DOI: https://doi.org/10.1084/jem.20201129, PMID: 32926098

Wang Y, Subramanian M, Yurdagul A, Barbosa-Lorenzi VC, Cai B, de Juan-Sanz J, Ryan TA, Nomura M, Maxfield FR, Tabas I. 2017. Mitochondrial Fission Promotes the Continued Clearance of Apoptotic Cells by Macrophages. *Cell* **171**:331–345. DOI: https://doi.org/10.1016/j.cell.2017.08.041, PMID: 28942921

Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, Feng T, Zhou L, Tang W, Zhan L, Fu X, Liu S, Bo X, Yu G. 2021. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. *Innovation* **2**:e100141. DOI: https://doi.org/10.1016/j.xinn.2021.100141

Yurdagul A, Subramanian M, Wang X, Crown SB, Ilkayeva OR, Darville L, Kolluru GK, Rymond CC, Gerlach BD, Zheng Z, Kuriakose G, Kevil CG, Koomen JM, Cleveland JL, Muoio DM, Tabas I. 2020. Macrophage Metabolism of Apoptotic Cell-Derived Arginine Promotes Continual Efferocytosis and Resolution of Injury. *Cell Metabolism* **31**:518-533. DOI: https://doi.org/10.1016/j.cmet.2020.01.001, PMID: 32004476

Zhu N, Wang W, Liu Z, Liang C, Wang W, Ye F, Huang B, Zhao L, Wang H, Zhou W, Deng Y, Mao L, Su C, Qiang G, Jiang T, Zhao J, Wu G, Song J, Tan W. 2020. Morphogenesis and cytopathic effect of SARS-CoV-2 infection in human airway epithelial cells. *Nature Communications* **11**:e3910. DOI: https://doi.org/10.1038/s41467-020-17796-z, PMID: 32764693

Zuniga M, Gomes C, Carson SE, Bender MT, Cotzia P, Miao QR, Lee DC, Rodriguez A. 2021. Autoimmunity to annexin A2 predicts mortality among hospitalised COVID-19 patients. *The European Respiratory Journal* **58**:2100918. DOI: https://doi.org/10.1183/13993003.00918-2021, PMID: 34244321

Zuo Y, Estes SK, Ali RA, Gandhi AA, Yalavarthi S, Shi H, Sule G, Gockman K, Madison JA, Zuo M, Yadav V, Wang J, Woodard W, Lezak SP, Lugogo NL, Smith SA, Morrissey JH, Kanthi Y, Knight JS. 2020. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. *Science Translational Medicine* **12**:eabd3876. DOI: https://doi.org/10.1126/scitranslmed.abd3876, PMID: 33139519